CD-30 positive T-immunoblastic cutaneous lymphoma

CD30阳性T免疫母细胞性皮肤淋巴瘤

更新于：2024-11-01

基本信息

别名

CD-30 positive T-immunoblastic cutaneous lymphoma、CD-30 positive T-immunoblastic cutaneous lymphoma (disorder)、CD30+ immunoblastic large T-cell cutaneous lymphoma

+ [1]

简介-

关联

项与 CD30阳性T免疫母细胞性皮肤淋巴瘤相关的药物

anti-CD30 Bispecific Antibody-armed anti-CD3-Activated Autologous T-cells(Medical College of Wisconsin)

靶点

CD3 x CD30

作用机制

CD3刺激剂 [+1]

在研机构

Medical College of Wisconsin

原研机构

Medical College of Wisconsin

在研适应症

间变性大细胞淋巴瘤 [+4]

非在研适应症-

最高研发阶段临床1/2期

首次获批国家/地区-

首次获批日期1800-01-20

项与 CD30阳性T免疫母细胞性皮肤淋巴瘤相关的临床试验

NCT05544968 / Not yet recruiting临床1/2期IIT

Phase I Dose Escalation and Expansion Study to Investigate the Safety, Tolerability, and Preliminary Efficacy of Anti-CD30 Bispecific Antibody-armed Anti-CD3-Activated Autologous T-cells (CD30 biAb-AATC) in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies

This first-in-human trial will assess the safety, feasibility, and efficacy of an immunotherapy with a novel CD30 antibody conjugated to a CD3 antibody that is preloaded onto a patient's own T-cells, generating a CD30 bispecific antibody-armed, anti-CD3-activated, autologous T-cells (CD30 biAb-AATC).

开始日期2024-12-01

申办/合作机构

Medical College of Wisconsin

100 项与 CD30阳性T免疫母细胞性皮肤淋巴瘤相关的临床结果

登录后查看更多信息

100 项与 CD30阳性T免疫母细胞性皮肤淋巴瘤相关的转化医学

登录后查看更多信息

0 项与 CD30阳性T免疫母细胞性皮肤淋巴瘤相关的专利（医药）

登录后查看更多信息

项与 CD30阳性T免疫母细胞性皮肤淋巴瘤相关的文献（医药）

2021-08-01·Journal of Medical Cases

Lymphomatoid Papulosis Development in Acute Lymphoblastic Leukemia

作者: Sato, Tomonobu ; Toriumi, Naohisa ; Oura, Kazumi ; Iguchi, Akihiro ; Sarashina, Takeo

Lymphomatoid papulosis (LyP) is a chronic, recurrent benign skin disease characterized by histological features of a CD 30-positive cutaneous T-cell lymphoproliferative disorder. It is rare, with an annual, worldwide incidence of 1.2 - 1.9 per million, and accounts for 16-47% of pediatric cutaneous lymphoproliferative disorders. It often occurs on the extremities or the trunk and rarely affects the face or genitals. Its onset may be triggered by irradiation therapy, immunomodulating agents, infection or atopic dermatitis. It has a benign course but is associated with certain hematological malignancies. Mycosis fungoides and primary cutaneous anaplastic large cell lymphoma are the most commonly associated hematological malignancies. The incidence of lymphoma in children with LyP has been reported to be 8.5% at most. Most patients who develop lymphomas do so within 4 years of the LyP onset; therefore, patients with LyP should be carefully followed up. Herein, we report a case in which tumors appeared in the left scrotum and under the left lip during maintenance therapy for precursor B-cell acute lymphoblastic leukemia. We needed to distinguish the tumor from extramedullary recurrence of ALL or de novo other cutaneous lymphoma; however, the histological findings of a tumor biopsy resulted in a diagnosis of LyP.

2018-04-01·Journal of Cutaneous Pathology

Cutaneous intravascular CD30+ T‐cell pseudolymphoma occurring in a regressing keratoacanthoma

作者: Crater, Scott E. ; Elston, Dirk M. ; Kailas, Ajay ; Cerruto, Carlos A.

Cutaneous intravascular CD30+ pseudolymphoma is an uncommon incidental finding that may mimic intravascular or angiotropic lymphoma. We describe a 78‐year‐old female with a traumatized regressing keratoacanthoma on her left cheek. A shave biopsy revealed intravascular staining of atypical lymphocytes positive for CD45, CD3 and CD30. Clinical exam revealed no other evidence of lymphoma, the patient denied constitutional symptoms, and routine blood work was normal. The patient is healthy and doing well 28 months after her first visit. CD30+ pseudolymphoma should be distinguished from malignant intravascular lymphoproliferative disorders.

2015-04-01·Journal of the European Academy of Dermatology and Venereology

Pyoderma gangrenosum‐like CD30+ cutaneous T‐cell lymphoma in a patient with mycosis fungoides

Letter

作者: Parodi, A. ; Scaparro, M. ; Pimpinelli, N. ; Cozzani, E. ; Pierri, I. ; Rongioletti, F.